// App-Quantinova.ai

4628 : Evaluation of Two Secondary Prophylaxis Regimens of Recombinant Factor IX(r-IX) in Moderately Severe to Severe( FIX ?2%) Hemophilia B Patients

Researchers

Presenter

  • Mary-Kate Barrette-Grischow

Principal Investigators

  • Lynne Smith

  • JM Korth-Bradley

  • Robert Charnigo

  • Frank E. Shafer

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Hemophilia

  • Venous thrombosis

  • Trauma

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • open label

  • randomized

  • cross over

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved